Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China’s Cellular Biomedicine Group Announces Reverse Merger

publication date: Jan 4, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cellular Biomedicine Group (CBMG), a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group. EastBridge is a US entity that helps companies (usually from China or other Asia-Pacific countries) go public. CBMG is testing progenitor and dendritic cell therapies as treatments for a wide variety of diseases, including cancer and osteoarthritis. Both of CMBG’s facilities are in China, and its products are aimed at the China market. More details....

Stock Symbol: (OTCQB: EBIG)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners